Rein Therapeutics
Clinical-stage biopharmaceutical organization focused on development of therapeutics for pulmonary diseases (including idiopathic pulmonary fibrosis). The site content highlights capabilities in clinical development and pharmacovigilance, CMC and cGMP manufacturing, process development and scale-up, translational research using genomic/proteomic approaches, and quality and regulatory preparedness.
Industries
Nr. of Employees
small (1-50)
Patents
Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
US-11905336-B2
View DetailsModified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
US-11787838-B2
View Details
Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
US-11905336-B2
View DetailsModified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
US-11787838-B2
View DetailsServices
Clinical program design and safety monitoring for investigational therapeutics.
Process engineering and scale-up for drug substance and drug product, including transfer to cGMP operations.
Quality systems, supplier management and preparation for regulatory inspections.
Use of genomic, proteomic and bioinformatic methods and preclinical humanized models for disease mechanism studies.
Clinical program design and safety monitoring for investigational therapeutics.
Process engineering and scale-up for drug substance and drug product, including transfer to cGMP operations.
Quality systems, supplier management and preparation for regulatory inspections.
Use of genomic, proteomic and bioinformatic methods and preclinical humanized models for disease mechanism studies.
Expertise Areas
- Clinical trial management
- Pharmacovigilance
- CMC and bioprocessing
- Process development and scale-up
Key Technologies
- Genomic analysis
- Proteomics
- Bioinformatics
- Humanized SCID mouse models
News & Updates
Press release reporting positive topline clinical data for LTI-03 in IPF (posted on the site).
Quarterly financial results and business update (posted on the site).
Notice of investor presentation.
Announcement related to cohort 2 data for LTI-03.
Quarterly financial results and business update (posted on the site).
Press release reporting positive topline clinical data for LTI-03 in IPF (posted on the site).
Quarterly financial results and business update (posted on the site).
Notice of investor presentation.
Announcement related to cohort 2 data for LTI-03.
Quarterly financial results and business update (posted on the site).